Hematopoietic Sphingosine 1-Phosphate Lyase Deficiency Decreases Atherosclerotic Lesion Development in LDL-Receptor Deficient Mice

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Bot, Martine ^a   Van Veldhoven, Paul P ^b   de Jager, Saskia C A ^a   Johnson, Jason ^c   Nijstad, Niels ^d   Van Santbrink, Peter J ^a   Westra, Marijke M ^a   Van Der Hoeven, Gerd ^b   Gijbels, Marion J ^e   Müller Tidow, Carsten ^f   Varga, Georg ^g   Tietge, Uwe J F ^d   Kuiper, Johan ^a   Van Berkel, Theo J C ^a   Nofer, Jerzy Roch ^f,h   Bot, Ilze ^a   Biessen, Erik A L ^a,e  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c BRISTOL ROYAL INFIRMARY   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g UNIVERSITY OF MÜNSTER   (Germany)

^h UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LYASE; SPHINGOSINE 1 PHOSPHATE LYASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHIMERA; CONTROLLED STUDY; CYTOKINE RESPONSE; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME DEFICIENCY; FEMALE; HEMATOPOIESIS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFER; LYMPHOCYTOPENIA; MACROPHAGE; MACROPHAGE ACTIVATION; MONOCYTE; MONOCYTOSIS; MOUSE; MYELOPOIESIS; NEUTROPHIL COUNT; NONHUMAN; PHENOTYPE; STROMA; T LYMPHOCYTE;

ALDEHYDE-LYASES; ANIMALS; ATHEROSCLEROSIS; BONE MARROW CELLS; CELL DIFFERENTIATION; FEMALE; HEMATOPOIESIS; LYMPHOCYTE COUNT; LYMPHOPENIA; LYSOPHOSPHOLIPIDS; MACROPHAGES; MICE; MICE, KNOCKOUT; NEUTROPHILS; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; RECEPTORS, LDL; SPHINGOSINE; SPLEEN;

EID: 84877896334     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063360     Document Type: Article

References (41)

1. Spiegel S, Milstien S, (2003) Sphingosine-1-phosphate: an enigmatic signaling lipid. Nat Rev Mol Cell Biol 4: 397-407.
2. Gardell SE, Dubin AE, (2006) Chun J Emerging medicinal roles for lysophospholipid signaling. Trends Mol Med 12: 65-75.
3. Yatomi Y, Ohmori T, Rile G, Kazama F, Okamoto H, et al. (2000) Sphingosine 1-phosphate as a major bioactive lysophospholipid that is released from platelets and interacts with endothelial cells. Blood 96: 3431-3438.
4. Hänel P, Andréani P, Gräler MH, (2007) Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J 21: 1202-1209.
5. Mitra P, Oskeritzian CA, Payne SG, Beaven MA, Milstien S, et al. (2006) Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci U S A 103: 16394-16399.
6. Rosen H, Goetzl EJ, (2005) Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 5: 560-570.
7. Goetzl EJ, Rosen H, (2004) Regulation of immunity by lysosphingolipids and their G protein-coupled receptors. J Clin Invest 114: 1531-1537.
8. Mandala S, Hajdu R, Bergstrom J, Quackenbush E, Xie J, et al. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296: 346-349.
9. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, et al. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277: 21453-21457.
10. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, et al. (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427: 355-360.
11. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, et al. (2005) Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309: 1735-1739.
12. Taha TA, Hannun YA, Obeid LM, (2006) Sphingosine kinase: biochemical and cellular regulation and role in disease. J Biochem Mol Biol 39: 113-131.
13. Venkataraman K, Thangada S, Michaud J, Oo ML, Ai Y, et al. (2006) Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem J 397: 461-471.
14. Garcia JG, Liu F, Verin AD, Birukova A, Dechert MA, et al. (2001) Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. J Clin Invest 108: 689-701.
15. Bolick DT, Srinivasan S, Kim KW, Hatley ME, Clemens JJ, et al. (2005) Sphingosine-1-phosphate prevents tumor necrosis factor-alpha mediated monocyte adhesion to aortic endothelium in mice. Arterioscler Thromb Vasc Biol 25: 976-981.
16. Gomez-Munoz A, Kong J, Salh B, Steinbrecher UP, (2003) Sphingosine-1-phosphate inhibits acid sphingomyelinase and blocks apoptosis in macrophages. FEBS Lett 539: 56-60.
17. Nofer JR, Bot M, Brodde M, Taylor PJ, Salm P, et al. (2007) FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 115: 501-508.
18. Miyamoto T, Matsumori A, Hwang MW, Nishio R, Ito H, et al. (2001) Therapeutic effects of FTY720, a new immunosuppressive agent, in a murine model of acute viral myocarditis. J Am Coll Cardiol 37: 1713-1718.
19. Peng X, Hassoun PM, Sammani S, McVerry BJ, Burne MJ, et al. (2004) Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am J Respir Crit Care Med 169: 1245-1251.
20. Fujii R, Kanai T, Nemoto Y, Makita S, Oshima S, et al. (2006) FTY720 suppresses CD4+CD44highCD62L- effector memory T cell-mediated colitis. Am J Physiol Gastrointest Liver Physiol 291: G267-274.
21. Hansson GK, Libby P, (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6: 508-519.
22. Keul P, Tölle M, Lucke S, von Wnuck Lipinski K, Heusch G, et al. (2007) The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 27: 607-613.
23. Poti F, Bot M, Costa S, Bergonzini V, Maines L, et al. (2012) Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice. Thromb Haemost 107: 552-561.
24. Skoura A, Michaud J, Im DS, Thangada S, Xiong Y, et al. (2011) Sphingosine-1-phosphate receptor-2 function in myeloid cells regulates vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol 31: 81-85.
25. Keul P, Lucke S, von Wnuck Lipinski K, Bode C, Gräler M, et al. (2011) Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis. Circ Res 108: 314-323.
26. Vogel P, Donoviel MS, Read R, Hansen GM, Hazlewood J, et al. (2009) Incomplete inhibition of sphingosine 1-phosphate lyase modulates immune system function yet prevents early lethality and non-lymphoid lesions. PLoS One 4: e4112.
27. Van Veldhoven PP, (2005) Sphingosine 1-phosphate lyase deficient mice. Chem Phys Lipids 136: 164-165.
28. Means CK, Miyamoto S, Chun J, Brown JH, (2008) S1P1 receptor localization confers selectivity for Gi-mediated cAMP and contractile responses. J Biol Chem 283: 11954-11963.
29. 't Hoen PA, Van der Lans CA, Van Eck M, Bijsterbosch MK, Van Berkel TJ, et al. (2003) Aorta of ApoE-deficient mice responds to atherogenic stimuli by a prelesional increase and subsequent decrease in the expression of antioxidant enzymes. Circ Res 93: 262-269.
30. Miller MJ, Wei SH, Parker I, Cahalan MD, (2002) Two-photon imaging of lymphocyte motility and antigen response in intact lymph node. Science 296: 1869-1873.
31. Weber C, Krueger A, Münk A, Bode C, Van Veldhoven PP, et al. (2009) Discontinued postnatal thymocyte development in sphingosine 1-phosphate-lyase-deficient mice. J Immunol 183: 4292-4301.
32. Tsou CL, Peters W, Si Y, Slaymaker S, Aslanian AM, et al. (2007) Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest 117: 902-909.
33. Hughes JE, Srinivasan S, Lynch KR, Proia RL, Ferdek P, et al. (2008) Sphingosine-1-phosphate induces an antiinflammatory phenotype in macrophages. Circ Res 102: 950-958.
34. Geissmann F, Jung S Littman DR, (2003) Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19: 71-82.
35. Auffray C, Fogg D, Garfa M, Elain G, Join-Lambert O, et al. (2007) Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 317: 666-670.
36. Johnson JL, Sala-Newby GB, Ismail Y, Aguilera CM, Newby AC, (2008) Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arterioscler Thromb Vasc Biol 28: 1647-1653.
37. Poti F, Costa S, Bergonzini V, Galletti M, Pignatti E, et al. (2012) Effect of sphingosine 1-phosphate (S1P) receptor agonists FTY720 and CYM5442 on atherosclerosis development in LDL receptor deficient (LDL-R(-/-)) mice. Vascul Pharmacol 57: 56-64.
38. Daum G, Grabski A, Reidy MA, (2009) Sphingosine 1-phosphate: a regulator of arterial lesions. Arterioscler Thromb Vasc Biol 29: 1439-1443.
39. Sakaguchi S, Ono M, Setoguchi R, Yagi H, Hori S, et al. (2006) Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 212: 8-27.
40. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, et al. (2006) Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12: 178-180.
41. Daly C, Rollins BJ, (2003) Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies. Microcirculation 10: 247-257.